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Ocular surgical models for immune and angiogenic responses
Takenori Inomata†, Alireza Mashaghi†, Antonio Di Zazzo†, and Reza Dana*
Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Department of 
Ophthalmology, Harvard Medical School, Boston, MA 02114, USA
Abstract
Corneal transplantation serves as a reproducible and simple surgical model to study mechanisms 
regulating immunity and angiogenesis. The simplicity of the model allows for systematic analysis 
of different mechanisms involved in immune and angiogenic privilege and their failures. This 
protocol describes how to induce neovessels and inflammation in an actively regulated avascular 
and immune-privileged site. This involves placing intra-stromal corneal sutures for two weeks, 
disrupting the privileges, and performing corneal transplantation subsequently. Privileged and 
non-privileged recipient responses to donor cornea can be compared to identify key 
immunological mechanisms that underlie angiogenesis and graft rejection. This protocol can also 
be adapted to the growing repertoire of genetic models available in the mouse, and is a valuable 
tool to elucidate molecular mechanisms mediating acceptance or failure of corneal graft. The 
model could be used to assess the potential of therapeutic molecules to enhance graft survival in 
vivo.
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BACKGROUND
Cornea is an avascular tissue and serves as a model system of choice for angiogenesis 
studies [1]. It actively works to establish an angiogenic privilege, which is essential for 
maintaining its transparency. Studies on corneal angiogenesis resulted in important insights 
into how angiogenesis is regulated, and in particular how blood and lymphatic neovessels 
can be inhibited or induced. Such studies led to the development of potential therapeutics for 
cardiovascular, neoplastic, and inflammatory diseases [2].
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Studying cornea angiogenesis (hemangiogensis and/or lymphangiogenesis) provides a 
platform for exploring different aspects of the immune response [3]. It is known that a 
foreign antigen is brought to regional lymphatic tissue via lymphatic vessels where it is 
specifically recognized. While lymphatic vessels act as afferent arm of the immune 
response, blood vessels deliver the effector immune cells to the site of insult, acting as 
efferent arm of the immune response [4]. Aberrant growth of these vessels in the cornea 
breaks its immune privilege [5]. The link between angiogenesis and immune system in the 
cornea is bidirectional because resident immune cells play a critical role in initiating and 
promoting angiogenesis.
Several approaches, involving the eye, have been applied to investigate different aspects of 
angiogenesis and immunity. A landmark discovery in oncology, showing the tumor-
mediated angiogenesis, emerged from introducing tumors into the anterior chamber of a 
rabbit eye [6]. Experimental eye models have been used to study allergic reactions to 
antigens [7] as well. Further it has been used to study cellular mechanisms that actively 
suppress immune responses such as melanocyte-stimulating hormone mediated immune 
regulation [8].
Our model allows for a comparative analysis of immune responses and the interplay 
between these responses and angiogenesis. It involves transplantation in an immune 
privilege context and non-immune privilege one by controlled induction of 
neovascularization [9]. Corneal transplantation is a common and clinically relevant way for 
studying the immune response to foreign antigens. The strength of our approach lies in its 
simplicity and cost effectiveness. An important advantage of corneal transplantation as a 
model is its accessibility and consequent ease of assessment for angiogenesis and 
immunological reaction. Since the original development of this model in early 90's [10, 11], 
our group along with others has been using this or adapted versions of the model to explore 
corneal immunity and angiogenesis for decades [9]. These efforts led to mechanistic 
understanding of immune tolerance and of secondary lymphangiogenesis [9].
Briefly, our protocol involves inducing inflammation and neovascularization in cornea and 
using it as a host bed for corneal transplant. Inflamed and neovascularized host beds carry a 
higher risk of graft rejection [9]. Neovascularization and inflammation is achieved by 
performing three butterfly intra-stromal corneal sutures in a well-defined arrangement. After 
at least two weeks, to have a proper and stable neovascularization, we graft an allogeneic 
cornea onto the high-risk bed [12]. We can then monitor the graft and perform in vivo and ex 
vivo assessments.
MATERIALS
Reagents
Male 6- to 8-week-old C57BL/6 mice are used as donors. Male 6- to 8-week-old Balb/c 
mice are used as allogeneic recipients. We recommend usage of age- and sex-matched mice 
to have less variable outcomes. Depending on the aim of the study, the technique can be 
applied to different strains, genders, ages and animal models for donor and recipient 
Inomata et al. Page 2
J Biol Methods. Author manuscript; available in PMC 2015 November 06.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
animals. Care must be taken in trying different options as the ones recommended here. For 
example it is known that grafting on C57BL/6 mice induces a stronger immune reaction.
✓ Ocular viscoelastic device (OVD), (Bausch & Lomb, Rochester, NY, USA, Cat. 
# 59081L)
✓ Propacaine hydrochloride ophthalmic solution 0.5% (wt/vol), (Bausch & Lomb 
Incorporated, Tampa, FL, USA, NDC 24208-730-06)
✓ Phenylephrine ophthalmic solution 5% (ALTAIRE Pharmaceuticals, Inc., 
Aquebogue, NY, USA, NDC 59390-193-13)
✓ Tropicamide ophthalmic solution 1% (Bausch & Lomb Incorporated, Tampa, 
FL, USA, NDC 24208-590-64)
✓ Triple antibiotic eye ointment (Bacitracine Zinc, Neomycin, polymyxin B 
Sulfates), (Bausch & Lomb Incorporated, Tampa, FL, USA, NDC 
24208-780-55)
✓ Ketamine (20 mg/kg)/Xylazine (100–200 mg/kg)
✓ Buprenorphine (0.05–0.1 mg/kg)
✓ Sterile Phosphate Buffer Saline (PBS), (Life Technologies Corporation, Grand 
Island, NY, USA, Cat. # 10010-031)
Equipment
✓ 11-0 nylon suture (MANI, Inc., Tochigi, Japan, Cat. # 0550S)
✓ 8-0 nylon suture (MANI, Inc., Tochigi, Japan, Cat. # 2056)
✓ Sterile Jeweler’s forceps (one blunt and one fine)
✓ Scissors (Vannas and curved)
✓ Sterile trephine, diameter 2 mm and 1.5 mm. (HealthLink, Jacksonville, FL, 
USA, Cat. # BP15, BP20)
✓ Sterile needles 25G and 30G
✓ Binocular microscope
✓ Slit lamp
✓ Eye spears (Beaver Visitec International, Inc., Waltham, MA, USA, Cat. # 
008680)
PROCEDURE
All animal experiments conducted in this protocol were approved by the Institutional 
Animal Care and Use Committee of the Schepens Eye Research Institute.
High-risk model
A mouse model of corneal neovascularization will be prepared using corneal sutures:
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1. Anesthetize mouse with intraperitoneal ketamine (120 mg/kg) and xylazine (20 
mg/kg) using a 25G needle.
2. Place mouse in a laterally recumbent position for surgical dissecting microscope 
visualization.
3. Cut the whiskers and eye lashes to have a clean operating field.
4. Wash the ocular surface with PBS and dry it using a sterile sponge (eye spears).
5. Apply one drop of anesthetic proparacaine 0.5% to the corneal surface prior to 
starting the procedure. Wait 1–2 min.
6. Dry the ocular surface using eye spears without touching the cornea.
7. Mark the central cornea with 1.5 mm trephine by softly touching the epithelium 
(Fig. 1A and 1B, Fig. 3A).
8. Place three intrastromal butterfly interrupted sutures (11-0 nylon) with two 
stromal incursions per suture, extending over 120° of the corneal circumference 
each. The sutures are positioned out of the marked area without reaching the 
limbus (Fig. 1C and 1D, Fig. 3B, Movie S1).
9. Apply antibiotic ointment.
10. Administer buprenorphine by subcutaneous injection through 25G needle 
immediately after surgery and every 12 h for 48 h to minimize post-operative 
pain.
11. The mice will be clinically evaluated under a surgical microscope and slit lamp 
every day for up to 2 weeks.
Allogeneic penetrating corneal transplantation
First, prepare the donor cornea and then operate on the recipient.
Donor preparation
12. Euthanize donor mouse using CO2.
13. Mark the central cornea with a 2 mm diameter trephine. Here, we recommend 
applying enough pressure to penetrate into deep stroma without perforating the 
cornea.
14. Tunnel into the anterior chamber from a point on the marked edge using a 30G 
needle. A proper tunneling would lead to leakage of aqueous humor and a partial 
collapse of the anterior chamber.
15. Inject OVD to rebuild the depth of the anterior chamber.
16. Carefully dry the surface with eye spears.
17. Partially excise the central donor cornea with Vannas scissors along the marked 
edge for 270 degrees (Fig. 2A).
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18. For less experienced hands we recommend to pass the suture through the free 
edge of the donor cornea. This is a critical step because suturing the donor on 
the recipient may be difficult otherwise.
19. Excise the complete cornea, while the suture is in place, by cutting the 
remaining attachment.
20. Rapidly transfer the cornea with suture into sterile PBS and keep it until the 
recipient bed is prepared.
Recipient preparation
21. Anesthetize mouse with intraperitoneal ketamine (120 mg/kg) and xylazine (20 
mg/kg) using a 25G needle.
22. Place mouse in a laterally recumbent position for surgical dissecting microscope 
visualization.
23. Cut the whiskers and eye lashes to have a clean operating field.
24. Wash the ocular surface with PBS and dry it using a sterile sponge (eye spears).
25. Apply one drop of anesthetic proparacaine 0.5% to the corneal surface prior to 
starting the procedure. Wait 1–2 min.
26. Apply one drop of phenylephrine and tropicamide each to dilate the pupil. Wait 
1–2 min.
27. Dry the ocular surface using eye spears without touching the cornea.
28. Remove the intrastromal sutures (Movie S2).
29. Mark the central cornea with a 1.5 mm diameter trephine. In this case, we 
recommend applying enough pressure to penetrate into deep stroma without 
perforating the cornea (Fig. 3D, Movie S3).
30. Tunnel into the anterior chamber from the marked edge using a 30G needle. A 
proper tunneling would lead to leakage of aqueous humor and a partial collapse 
of the anterior chamber. Particular care should be taken to avoid touching lens 
and iris.
31. Inject OVD to rebuild the depth of the anterior chamber.
32. Carefully dry the surface with eye spears.
33. Excise the complete central host cornea with Vannas scissors along the marked 
edge (Movie S3).
34. Secure the 2.0 mm diameter donor cornea button to the prepared recipient bed of 
1.5 mm diameter with 8 interrupted 11–0 nylon sutures to keep a deep anterior 
chamber (Fig. 2C, 2D, Fig. 3E, Movie S4).
35. Inject OVD into anterior chamber during the procedure to maintain intraocular 
structure. We strongly recommend injecting OVD after placement of the first 
four sutures.
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36. Wash the anterior chamber with PBS to remove OVD at the end of the 
procedure.
37. Keep the contralateral eye moist by using triple antibiotic ointment during the 
procedure.
38. Apply antibiotic ointment to the operated eye.
39. Close the eyelid for 24 h with 8-0 nylon sutures (tarsorrhaphy, avoids contact 
between sutures and orb).
40. Administer buprenorphine (0.05–0.1 mg/kg) by subcutaneous injections with a 
25G needle immediately after surgery and every 12 h for 48 h to minimize post-
operative pain.
41. Remove the eyelid sutures at 24 h post-transplantation in anesthetized recipients 
under a dissecting microscope with needles.
42. Remove 8 interrupted 11-0 nylon sutures at day 7 post transplantation.
Clinical assessment
Examine all grafted eyes using a slit lamp microscopy, and exclude grafts with technical 
difficulties (hyphema, infection, loss of anterior chamber). Examine grafts weekly by slit-
lamp microscopy for edema, opacity, and neovascularization. Use a standard scoring system 
[13] (see Table 1) to describe the extent of opacity and neovascularization. Grafts with an 
opacity score of 2+ or greater 3 weeks after transplantation are considered rejected 
(immunologic failure). Grafts with an opacity score of 3+ or greater at 2 weeks post-
transplantation that never clear are also considered rejected.
ANTICIPATED RESULTS
Introducing intrastromal sutures as described here will lead to growth of sprouting vessels 
within 1 to 2 days. Within few days a prominent neovascularization should be established in 
more than two quadrants of the cornea, which is minimally needed for an effective high-risk 
model (Fig. 2B, Fig. 3C).
Allogeneic corneal transplantation onto a vascularized and inflamed host bed, as described 
in our model, succeeds in 90% of the cases by the end of two weeks post transplantation. 
After 4 weeks, the graft survival rate will decrease to 50% (Fig. 3F). In contrast, in the 
absence of inflammation and aberrant vessels the rate of rejection is dramatically reduced 
and no grafts are rejected two weeks after transplantation [14, 15].
Our model allows for detailed analysis of immune pathways involved, including Th1 
immune response, regulatory effect of T cells and pro-inflammatory and tolerogenic 
capacity of antigen presenting cells. We also use this model to study the role of innate and 
adaptive immunity in angiogenesis. All these are possible by not only using the eye tissues 
but also assessing the changes in the draining lymph node and spleen. Moreover, this model 
can be used with knockout and transgenic mice to evaluate various molecular pathways 
participating in immune response and angiogenesis.
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A number of other models for high-risk corneal beds have been used previously and may 
complement the model proposed in this paper. The cornea micropocket assay [16] been used 
for such studies for decades; however, over time the assay has been replaced by the surgical 
procedure described in our paper which may has many advantages such as reproducibility, 
low cost, and easy feasibility. In the micropocket assay, the vessels are induced by a not 
discriminated combination of injury and drugs, and the success of the micropocket technique 
highly depends on the ability of the surgeon. Slight changes in the procedure and device 
inserted into the eye can result in very high variations of vessel induction. In contrast, using 
the suture model presented in this protocol induces homogenously distributed neovessels in 
all four quadrants of the cornea. We note that the model presented here does not serve as a 
generic model for all high-risk settings. For instance, patients with allergic background carry 
high risk for rejection. Here, we recommend usage of allergic mouse models [7]. Alkali 
burns to murine cornea also serve as suitable model systems for patients with accidental 
exposure to a number of chemicals [17]. Corneal alkali burn leads to severe 
neovascularization, however, the underlying damage to the cornea is biologically complex 
and we have limited control on the extent of the damages (in contrast to the suture model) 
that may involve limbal areas among others. Thus, it is relatively hard to disentangle the role 
of various contributing factors (immunologic and non-immunologic). Overall, the 
simplicity, availability, and the cost of the described model provide a unique platform to 
study basic principles of immunity and angiogenesis beyond ophthalmic issues.
TROUBLESHOOTING
During the procedure one may encounter a number of problems. Here we list potential issues 
and explain how one can do troubleshooting.
1. During introduction of intra-stromal sutures, one may occasionally perforate the 
cornea. This is evidenced by leakage of the humor and a subsequent Siedel sign 
(Fig. 4). In this case, the immune privilege of the anterior chamber is compromised. 
The compromised cornea should be discharged.
2. Cataract is a major complication that results from touching the capsule of the lens 
while preparing the recipient. In this case, an undesired inflammatory reaction 
against the lens antigens will suddenly rise.
3. In case of incomplete removal of the OVD from the anterior chamber, we will face 
a high risk of intra ocular hypertension.
4. A severe complication is bleeding in the anterior chamber and subsequent hyphema 
formation. This is often related to cutting the iris during the procedure as well as to 
sudden decrease of the intraocular pressure during or after the procedure. 
Sometimes it can be caused by ingrowing neovessels into the anterior chamber 
after suture placement.
5. At the end of the procedure, it is important to check the tightness of the sutures and 
the arrangement of the graft edge for avoiding humor leakage and iris trap.
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6. For phenylephrine administration, we suggest to administer the drug carefully to 
avoid airways and oral mucosa adsorption. Systemic adsorption of the drug leads to 
cardiovascular and respiratory dysfunctions.
7. Late removal of tarsorrhaphy may lead to surface inflammation and an increased 
rejection rate.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Intra-stromal suture placement
A and B. Marking the cornea. C. Suture positioning between the limbus and marked ring. D. 
Three butterfly sutures.
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Figure 2. Allogenic corneal transplantation
A. Donor preparation. B. Vascularized and inflamed host bed. C. The graft after placement 
of four sutures. D. Allografted cornea.
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Figure 3. Schematic drawing of the surgical procedure
A. Mark the central cornea with 1.5 mm trephine. B. Place three intra-stromal butterfly 
interrupted sutures. C. Vascularized and inflamed host bed. D. Mark the central donor 
cornea with 1.5 mm trephine. E. Donor cornea is transplanted onto vascularized cornea bed 
of the host. F. Rejected graft with vessel ingrowth and opacity.
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Figure 4. Corneal perforation
Perforation is a main complication of intra-stromal suture placement. Positive Siedel sign.
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Table 1
Graft scoring based on corneal opacity and neovascularization.
Score Clinical manifestations
0 Clear
1 Minimal superficial opacity, iris vessels readily visible
2 Minimal deep (stromal), opacity, iris vessels still visible
3 Moderate stromal opacity, only pupil margin visible
4 Intense stromal opacity, only portion of pupil margin visible
5 Maximal stromal opacity, anterior chamber not visible
Score Clinical manifestation
0 No vessels
1 Vessels bed only (1–2 quadrants)
2 Vessels bed only (3–4 quadrants)
3 Vessels recipient graft border (1–2 quadrants)
4 Vessels recipient graft border (3–4 quadrants)
5 Vessels peripheral donor stroma (1–2 quadrants)
6 Vessels peripheral donor stroma (3–4 quadrants)
7 Vessels central donor stroma (1–2 quadrants)
8 Vessels central donor stroma (3–4 quadrants)
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